Momenta Pharmaceuticals provides update on generic Lovenox litigation

Links shared publicly online about this topic.

920
total visits

Momenta Pharmaceuticals provides update on generic Lovenox litigation

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that on August 25, 2010, the United States District Court for the District of Columbia denied sanofi-aventis U.S. LLC's request for a preliminary injunction directing the FDA to suspend and withdraw its approval of the Abbreviated New Drug Application (ANDA) filed by the Company's collaboration partner, Sandoz, for enoxaparin sodium injection USP, a generi

View full resource at news-medical.net

Tags: Deep Venous Thrombosis Medication, Drug, Pharma, FDA, Lovenox, Sanofi-Aventis, Litigation